Tetraphase Pharmaceuticals (NASDAQ:TTPH) issued its earnings results on Tuesday. The biopharmaceutical company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.18, Bloomberg Earnings reports. Tetraphase Pharmaceuticals had a negative net margin of 1,382.33% and a negative return on equity of 88.27%.
Tetraphase Pharmaceuticals (TTPH) opened at $2.75 on Wednesday. Tetraphase Pharmaceuticals has a one year low of $2.05 and a one year high of $9.93.
In other news, insider Jacques Dumas sold 8,750 shares of Tetraphase Pharmaceuticals stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $6.22, for a total transaction of $54,425.00. Following the completion of the transaction, the insider now owns 8,750 shares of the company’s stock, valued at approximately $54,425. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 5.50% of the company’s stock.
Several equities research analysts have commented on the stock. WBB Securities assumed coverage on shares of Tetraphase Pharmaceuticals in a research report on Thursday, February 22nd. They set a “speculative buy” rating and a $6.00 target price on the stock. SunTrust Banks restated a “buy” rating and set a $10.00 target price on shares of Tetraphase Pharmaceuticals in a research report on Wednesday, February 14th. Stifel Nicolaus decreased their target price on shares of Tetraphase Pharmaceuticals from $13.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, February 14th. BMO Capital Markets downgraded Tetraphase Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 price target for the company. in a research note on Wednesday, February 14th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $8.00 price target on shares of Tetraphase Pharmaceuticals in a research note on Wednesday, February 14th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. Tetraphase Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $9.84.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.